SCHEMBL24327660

SCHEMBL24327660

CN1CCN(C2CCN(c3ccc(N)c4c3CC(C)(C)O4)CC2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
PTK2B Q14289 1/20 0.38
ADRA2C P18825 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
ALDH1A1 P00352 3/20 0.35
POLB P06746 1/20 0.35
ACVR1 Q04771 3/20 0.34
FLT3 P36888 3/20 0.34
EML4 Q9HC35 3/20 0.34
ALK Q9UM73 3/20 0.34
RET P07949 2/20 0.34
ROS1 P08922 2/20 0.34
VCP P55072 1/20 0.34
L3MBTL3 Q96JM7 2/20 0.33
PIM1 P11309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661314 1.00 KDM4E (0.38) KDM4EGAAMAPTMAPK1HTT
SCHEMBL12862621 0.89 L3MBTL1 (0.43) GAAMAPTMAPK1HTTRECQL
SCHEMBL29661478 0.87 KDM4E (0.49) KDM4EGAAMAPTMAPK1HTT
SCHEMBL24328562 0.87 KDM4E (0.49) KDM4EGAAMAPTMAPK1HTT
SCHEMBL26655610 0.82 ALDH1A1 (0.40) KDM4EMAPTMAPK1HTTALDH1A1
SCHEMBL24328518 0.80 ALDH1A1 (0.40) KDM4EGAAMAPTMAPK1HTT
SCHEMBL26655419 0.80 GAA (0.39) KDM4EGAAMAPTMAPK1HTT
SCHEMBL24327498 0.79 TIPARP (0.34) KDM4EGAAHTTALDH1A1POLB
SCHEMBL29661397 0.79 TIPARP (0.34) KDM4EGAAHTTALDH1A1POLB
SCHEMBL24327352 0.76 POLB (0.41) KDM4EGAAMAPTMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 KDM4E 2783/4885GAA 3025/4885MAPT 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.